Our lead scientist Jennifer Bolsée will provide an update on our NKG2D-based multi-specific CAR T-cells at the advances in CAR T-cell engineering session on June 22nd.
If you want to know how NKG2D-based dual CAR T-cells could help to overcome antigen escape and improve anti-tumor efficacy, come to attend her presentation!
